RAF1 and neoplasm: In comparison to selective BRAFV600E inhibitors, LY3009120 has shown inhibitory effects in a wider range of tumor cells including RAF/RASmut and WT in vivo and in vitro [17,18,19,20,21,22,23,24,25].